瑞尔迈达疗法与派罗创世通过私募配售筹集资金

关键事实

1Relmada Therapeutics (RLMD) announced an oversubscribed $160.0 million private investment in public equity (PIPE) financing.

2Relmada's financing included participation from major institutions like Venrock Healthcare Capital Partners, Janus Henderson Investors, and RA Capital Management.

3PyroGenesis (PYR) announced its intention to complete a non-brokered private placement to raise up to $1,000,000 at $0.54 per unit.

瑞尔迈达疗法公司 (RLMD) 已成功宣布完成一项超额认购的1.6亿美元私募股权投资 (PIPE) 融资。本轮融资吸引了Venrock Healthcare Capital Partners、Janus Henderson Investors 和 RA Capital Management等顶级机构投资者的浓厚兴趣。这些资金将专门用于推进瑞尔迈达疗法公司针对肿瘤学和中枢神经系统 (CNS) 适应症的临床阶段疗法。与此同时，派罗创世公司 (PYR) 披露计划完成一项非经纪私募配售，以筹集高达100万美元。派罗创世的此次发行定价为每单位0.54美元，旨在为其等离子体技术运营提供必要的流动性。瑞尔迈达疗法公司获得的强大机构支持凸显了市场对其研发管线的信心，而派罗创世则为工业增长筹集资金。

免费注册以访问此内容

创建免费账户

来源: